Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EB103 · 1 trial · 15 indications
Type, frequency, and severity of adverse events (AEs), including treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), clinically significant laboratory abnormalities recorded as AEs, and AEs leading to permanent discontinuation.
RP2D based on maximum tolerated dose (MTD) (if reached), overall safety, preliminary efficacy, and manufacturing capability.
| Arm | Type | Description |
|---|---|---|
| EB103 | EXPERIMENTAL | Experimental: Dose Escalation, RP2D Confirmatory, and Expansion (Phase 1/2 Single Arm) Dose Escalation Cohort: Participants receive a single infusion of EB103 at one of two predefined dose levels on Day 0 (completed). RP2D Confirmatory Cohort: Participants receive EB103 at the RP2D on Day 0. Expansion Cohort: Participants receive an initial EB103 T-cell infusion at the RP2D on Day 0 followed by a second EB103 T-cell infusion administered according to the protocol-defined schedule. |
| Name | Type | Description |
|---|---|---|
| EB103 | BIOLOGICAL | EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene. |
Inclusion Criteria: * Age 18 years or older at the time of informed consent * Histologically confirmed R/R B-cell non-Hodgkin's lymphoma (NHL) * Adequate organ function * Relapsed or refractory disease 1. Relapsed or refractory disease, defined as ONE OR MORE of the following modified SCHOLAR-1 ...
EB103 is an investigational T-cell therapy being developed by Estrella Immunopharma, Inc. for adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. It is in Phase 1 clinical development and is designed to target the CD19 protein found on B cells.
EB103 is being studied for the treatment of adults with relapsed or refractory B-cell non-Hodgkin's lymphoma, including subtypes such as large B-cell lymphoma, high-grade B-cell lymphoma, CNS lymphoma, and HIV-associated lymphoma. It is investigational and has not been approved for commercial use.
EB103 targets CD19, a protein expressed on the surface of B cells. By directing T-cell activity toward CD19, EB103 is designed to attack malignant B cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
EB103 is being developed by Estrella Immunopharma, Inc., a company whose common stock trades under the ticker symbol ESLA. Estrella Immunopharma is the sponsor responsible for advancing EB103 through clinical development in oncology.
EB103 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 program is evaluating EB103 in adults with relapsed or refractory B-cell non-Hodgkin's lymphoma.
EB103 is being evaluated in one active clinical trial, NCT06343311, titled T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). The Phase 1 study is currently recruiting an estimated 27 participants in the United States and is open to adults aged 18 years and older.